Analysis of the risk factors associated with bloodstream infections caused by Candida parapsilosis in pediatric patients and the determinants of fluconazole non-susceptibility: a retrospective 15-year cohort study

Read full text
Authors: Zümrüt Şahbudak Bal, Sema Yıldırım Arslan, Gizem Güner Özenen, Gülizar Turan, Kübra Cebeci, Ülgen Çeltik, Gülhadiye Avcu, Nihal Karadaş, Gülcihan Özek, Miray Karakoyun, Dilek Yeşim Metin, Süleyha Hilmioğlu Polat
Cited by: 0
References: 23

Abstract

BACKGROUND: In recent decades, infections caused by C.parapsilosis have been increasingly reported, particularly strains of C.parapsilosis that are non-susceptible to fluconazole. AIMS: We aimed to evaluate candidemia episodes caused by C. parapsilosis (CP) and compare them with candidemia episodes caused by non-parapsilosis Candida spp. (non-CP). Furthermore, we examined the risk factors and outcomes of C.parapsilosis candidemia based on fluconazole susceptibility [fluconazole susceptible: FS, fluconazole non-susceptible: FNS] from January 2008 to December 2022 at Ege University. RESULTS: Of the 423 episodes of candidemia, C.parapsilosis was the most common, identified in 195 cases (46.1%). The rate of fluconazole non-susceptibility was 48.3%. Multivariate analysis indicated that fluconazole exposure and the presence of tracheostomy were significant risk factors for C. parapsilosis candidemia (32.3% vs. 18.9%; p =0.006 ; OR = 1.917; 95% CI:1.210–3.037) and (12.8% vs. 5.7%; p = 0.047; OR = 2.125 (1.010-4.469), respectively. The attributable mortality(AM) rate and crude mortality(CM) rates were slightly higher in the non-CP group than in the CP group without a significant difference (p > 0.005). Fluconazole non-susceptibility was significantly associated with antifungal exposure (p = 0.047; OR = 2.119; 95% CI = 1.012–4.437) and did not alter outcomes, including AM and CM (p > 0.05). CONCLUSIONS: This study identified significant associations between fluconazole exposure and tracheostomy with subsequent C.parapsilosis candidemia. Notably, antifungal exposure was the only clinical risk factor identified for the development of fluconazole resistance. The increasing incidence of fluconazole resistance should prompt clinicians to consider using an echinocandin in empirical therapy. CLINICAL TRIAL NUMBER: Not applicable.

Fields of Study & Subjects

Antifungal resistance and susceptibility Nail Diseases and Treatments Fungal Infections and Studies

Publication details

Journal / source
BMC Infectious Diseases
Volume
26
Issue
1
Pages
278–278
Publication date
8 January 2026
Language
EN